16 November 2011
Neuron Bio makes approaches to cutting-edge biotechnological projects in Silicon Valley
Last week representatives of Neuron Bio visited Silicon Valley, the most innovative business complex in the world, where they got to see how some of the most important companies in the world work, not only in the field of biotechnology but also in the internet and telecommunications sector.
Among the companies visited by the Neuron Bio party were Rinat, a biotech company acquired by Pfizer, and the biotechnology business incubator San Jose Biocenter, where they had a meeting with some of the management staff.
Neuron Bio undertook this trip along with some twenty other winners of the XXI Prize for Business Enterprise (Premio Emprendedor XXI), awarded by La Caixa savings bank. At Pfizer there was a working session with Jaume Pons, vice-chairman of Pfizer, and Meritxell Galindo, who work together at Rinat.
The aim of this award, according to a spokesman for La Caixa, is to undertake market research, analyse commercial opportunities and find out more about the business reality of companies housed in Silicon Valley. Apart from Pfizer, the party visited emblematic companies such as Google, Agilent Technologies and such symbolic institutions as Stanford University.
Neuron Bio and the rest of companies on this fact-finding trip had the opportunity to meet Spanish businessmen and women who had moved to the USA to work. Their personal and professional experiences provide the most tangible example of how it is possible to create a company with a global vision.
During this seven-day visit, there were meetings with Santiago Arano, CEO of Softonic for North America; Eneko Knorr, the founder of Ideateca; Miguel Angel Diez, the founder of Red Karaoke, who set themselves up in Silicon Valley two months ago; Maria Alegre, a young entrepreneur, who has just received an investment of 2M$ for her company, Chartboost; Félix González Herranz, who is studying a programme of entrepreneurship at Stanford University; José María García, in charge of new strategies for Google; and specialists from Osborne Clarke and Joaquim Trias, one of the reference names for biotechnology in the USA.